
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About
Intensity Therapeutics, Inc. Common stock (INTS)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: INTS (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $3.33
1 Year Target Price $3.33
1 | Strong Buy |
2 | Buy |
2 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -60.26% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 14.05M USD | Price to earnings Ratio - | 1Y Target Price 3.33 |
Price to earnings Ratio - | 1Y Target Price 3.33 | ||
Volume (30-day avg) 5 | Beta 3.78 | 52 Weeks Range 0.19 - 4.35 | Updated Date 08/15/2025 |
52 Weeks Range 0.19 - 4.35 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.82 |
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.16 | Actual -0.13 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -122.68% | Return on Equity (TTM) -334.12% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 11555740 | Price to Sales(TTM) - |
Enterprise Value 11555740 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -4.72 | Shares Outstanding 47057700 | Shares Floating 40822108 |
Shares Outstanding 47057700 | Shares Floating 40822108 | ||
Percent Insiders 13.25 | Percent Institutions 5.54 |
Upturn AI SWOT
Intensity Therapeutics, Inc. Common stock
Company Overview
History and Background
Intensity Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel, targeted cancer immunotherapies. Founded to improve outcomes for patients with difficult-to-treat cancers, the company leverages its proprietary DfuseRxSM technology platform.
Core Business Areas
- Drug Development: Research and development of novel cancer therapies using the DfuseRxSM platform, focusing on intratumoral injections to deliver potent anti-cancer agents directly into tumors.
Leadership and Structure
Lewis H. Bender serves as the Chief Executive Officer and President. The company has a board of directors and a management team overseeing research, development, and clinical trials.
Top Products and Market Share
Key Offerings
- INT230-6: INT230-6 is Intensity Therapeutics' lead product candidate, an investigational product designed for direct intratumoral injection. It is being evaluated in Phase 1/2 clinical trials for advanced solid tumors. Market share information is not currently available as this is an investigational drug. Competitors in immuno-oncology include major pharmaceutical companies like Merck (MRK), Bristol Myers Squibb (BMY), and Roche (RHHBY).
Market Dynamics
Industry Overview
The oncology market is experiencing rapid growth, driven by advancements in immunotherapy and targeted therapies. There is a significant unmet need for effective treatments for patients with advanced and resistant cancers.
Positioning
Intensity Therapeutics aims to differentiate itself through its DfuseRxSM platform, which allows for direct delivery of anti-cancer agents into tumors, potentially enhancing efficacy and reducing systemic toxicity.
Total Addressable Market (TAM)
The global oncology market is estimated at hundreds of billions of dollars. Intensity Therapeutics aims to capture a portion of this market by addressing difficult-to-treat cancers through its innovative approach.
Upturn SWOT Analysis
Strengths
- Proprietary DfuseRxSM platform
- Targeted intratumoral drug delivery
- Potential for enhanced efficacy and reduced toxicity
- Experienced management team
Weaknesses
- Limited financial resources
- Early-stage clinical development
- Reliance on a single lead product candidate
- High risk of clinical trial failure
Opportunities
- Positive clinical trial results
- Strategic partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
- Potential for breakthrough therapy designation
Threats
- Competition from established immuno-oncology therapies
- Regulatory hurdles and delays
- Unfavorable clinical trial outcomes
- Difficulty securing financing
Competitors and Market Share
Key Competitors
- Merck (MRK)
- Bristol Myers Squibb (BMY)
- Roche (RHHBY)
Competitive Landscape
Intensity Therapeutics faces intense competition from established pharmaceutical companies with significantly greater resources. Its competitive advantage lies in its novel DfuseRxSM platform, which could potentially offer a differentiated approach to cancer immunotherapy.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by progress in clinical trials and milestones achieved in drug development.
Future Projections: Future growth is dependent on the success of clinical trials and regulatory approvals. Analyst estimates vary widely given the inherent risks in drug development.
Recent Initiatives: Recent initiatives include enrollment in ongoing clinical trials for INT230-6 and presentations at medical conferences.
Summary
Intensity Therapeutics is a clinical-stage company focused on innovative cancer therapies using its DfuseRxSM platform. The company faces significant challenges, including competition from larger pharmaceutical companies and the inherent risks of drug development. Positive clinical trial results and strategic partnerships are critical for the company's future success. The focus on difficult to treat tumors sets them apart from the normal cancer therapeutics.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Intensity Therapeutics' website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investing in biotechnology companies carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Intensity Therapeutics, Inc. Common stock
Exchange NASDAQ | Headquaters Shelton, CT, United States | ||
IPO Launch date 2023-06-30 | Founder, President, CEO & Chairman of the Board Mr. Lewis H. Bender M.A., M.B.A., M.S. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | |
Full time employees 5 |
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.